Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CDK9 | P50750 | 3/20 | 0.37 |
| ▸ | CCNK | O75909 | 2/20 | 0.37 |
| ▸ | CCND3 | P30281 | 2/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.36 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24327589 | 0.79 | AHR (0.50) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL29661324 | 0.79 | AHR (0.50) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL2062564 | 0.77 | IGF1R (0.54) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL30184233 | 0.76 | ALK (0.44) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL24752703 | 0.76 | ALK (0.44) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL24620238 | 0.74 | MAPK10 (0.43) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL29190654 | 0.74 | ALK (0.42) | ALKULK1CCNA2CDK2CDK9 | |
| SCHEMBL2061222 | 0.73 | ALK (0.71) | ALKCDK9MAPK9MAPK10AURKA | |
| SCHEMBL31512671 | 0.73 | ALK (0.71) | ALKCDK9MAPK9MAPK10AURKA | |
| SCHEMBL24073485 | 0.73 | AKT1 (0.40) | ALKULK1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| EP-2318392-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-11 | — | — | EP | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| EP-2190826-A2 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009032668-A2 | 2 -BIPHENYLAMINO-4 -AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IGF1R, IRS1, IP6K1 | ALK 4/4885ULK1 246/4885CCNA2 1244/4885 |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, IGFBP1, IRS1 | ALK 5/4885ULK1 323/4885CCNA2 1055/4885 |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | ALK 14/4885ULK1 309/4885CCNA2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.